BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Non-Squamous Non-Small Cell Lung Cancer in China

    NEXT STORY
    Roche’s IPATential150 study evaluating ipatasertib in combination with abiraterone and prednisone/prednisolone met one of its co-primary endpoints
    PREV STORY
    CB2 Insights Announces Record Annual Revenue of $13.4 million for FY 2019 Sequential Growth of 25%
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Bionik Laboratories Announces Option to License Robotics Technology from the University of Texas at Dallas

    TORONTO and BOSTON, March 30, 2017 (GLOBE NEWSWIRE) -- Bionik Laboratories Corp. (OTCQX:BNKL) (“Bionik” ...

    author_avatar
    NASDAQ Market News

    Dr. Judith K. Glann, DNP/MSN/ACNP-BC/CCRN, is appointed to the American Health Council for Best in Nursing

    NEW YORK, Aug. 21, 2017 (GLOBE NEWSWIRE) -- Currently a Trauma/Surgical ICU Critical Care ...

    author_avatar
    NASDAQ Market News

    TLC and Jixi Biotechnology Partners Announce Joint Venture

    TAIPEI, Taiwan, Jan. 23, 2018 (GLOBE NEWSWIRE) -- TLC (4152.TT) today announced that it ...

    author_avatar
    NASDAQ Market News